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Abstract
Neurodegenerative diseases are characterized by a
progressive deterioration of brain function, with a
significantly consequent decrease in the quality of life of
patients and their families. Due to increasing life
expectancy, the incidence of these diseases has increased
over the years, and has been under research.
Objective: The aim of this paper is to systematically
review the scientific literature about the evaluation of life’
quality in patients with neurodegenerative diseases.
Methods: Reflective systematic literature review on
Pubmed, MedLine and Scopus database with the
keywords "quality of life of Patients" and
"neurodegenerative diseases" was analyzed. It was
analyzed in the period between 2000 and 2015. PRISMA
criteria reporting of systematic reviews and meta-analyses
were applied. The inclusion criteria were: usage of
instrument to measure life’ quality, presenting
quantitative or qualitative results, and psychometric
studies. It was excluded articles reviews outside the scope
of the subject, theoretical articles and new therapies,
diagnostic and palliative care.
Results: After applying the methodology, five scientific
articles were included in the study. The measuring
instruments were used the dimensions (physical, mental,
social and environmental) were analyzed. It was analyzed
the results obtained in the studies.
Conclusions: This literature review indicated that more
research is needed to assess the impact of quality of life in
patients with degenerative pathologies. The implications
of these findings and potential directions for future
research are discussed.
Keywords: Quality of life; Neurodegenerative diseases;
Patients
Introduction
Neurodegenerative diseases result from the gradual
degeneration and/or death of neurons (cells responsible for
the nervous system functions). This degradation can affect
body movement and brain function, causing dementia
(progressive or chronic decline of cognitive function that
affects memory, thinking, behaviour, language, calculation,
learning and emotion capacity, and should never be associated
with a normal aging process) [1].
These diseases are one of the most important medical and
socio-economic problems of our time, affecting people of all
ages. The causes of their appearance are not known; they can
be different diseases: Alzheimer's disease (AD); Parkinson's
disease (PD); Amyotrophic Lateral Sclerosis (ALS); Multiple
Sclerosis (MS); Huntington's disease (HD); Machado-Joseph
disease; Amyloid Polyneuropathy Family, being the best
known, Alzheimer's and Parkinson's disease [2].
Neurodegenerative diseases have a major impact at
professional, social and family level of patients and can lead to
a complete inability to carry out any type of everyday activity.
For example, patients may have: motors problems; breathing
difficulties; cognitive problems or gradual memory loss
(possibly affecting the memory of all that has been learned
over a lifetime).
The major problem is that these disorders are normally
detected late and restricting the efficacy of the treatment
options.
Therefore, it is essential to support scientific research in this
area, to accelerate the discovery of the causes and
mechanisms of neurodegenerative diseases and develop
preventive treatments, better suited to the symptoms of each
disease. Similarly it is important to assess the impacts of
diseases in dimensions of Health-Related Quality of Life
(HRQoL), there have been few studies in this area [3].
The measures of HRQoL include physical, psychological and
social dimensions [1-4]. Physical component summary (PCS)
and mental component summary (MCS) are two measures of
HRQoL (present on short form health survey). Other measures
of HRQoL are Activities of daily living (ADL) and Instrumental
activities of daily living (IADL), which are two measures of self-
maintenance and autonomy [1].
Few studies of quality of life in patients with
neurodegenerative disease have been done. However, the
World Health Organization (WHO) has developed cross-
culturally, two generic instruments to assess the quality of life
(WHOQOL-100 and WHOQOL-BREF). Afterwards, due to
studies of large scale that includes many factors or many
situations where it is necessary an indicator of life’ quality of
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rapid assessment, the EUROHISQOL 8 – index was developed
(adapted of the WHOQOL-100 and WHOQOL-BREF).
In this article, it is also referenced to a new WHOQOL-DIS,
which aims to complement the WHOQOL-BREF, assessing
other dimensions [5]. Moreover, it will be mentioned the
HRQoL which includes physical, psychological and social
dimensions (Wilson and Cleary Model) [1].
It should be noted that currently there is no systematic
literature review that provides an insight into the quality of life
in patients with neurodegenerative disease by focusing on
psychosocial factors. In addition, systematic studies on this
subject are reduced. Thus, the aim of this study is to provide
an overview of the scientific evidence produced on that topic
or subject.
Methods
We conducted a study of reflective systematic literature
review. Between 2000 and 2015, we identified scientific
published papers in international journals, using a database
research in digital format, MedLine and PubMed, and in a
second phase to Scopus. The descriptors used in the research
were: ["quality of life and neurodegenerative diseases"]. Later,
because of the high number of matches (5099 publications),
the research was refined to ["quality of life" and
"neurodegenerative diseases”], obtaining 262 publications;
then it was made a new research with the keywords ["quality
of life of patients" and "neurodegenerative diseases"] (162
abstracts published). The study was restricted to published
English articles.
The research with the final descriptors ["quality of life of
patients" and "neurodegenerative diseases"] resulted in 162
publications in PubMed database, 16 publications in MedLine
and 16 publications in Scopus. It was analyzed 162 publications
obtained in the PubMed database, form excluded 151
publications: 88 publications were outside the scope of the
study, they were related to other pathologies or out of context
themes; 21 were related to the issue of gene and/or cell
therapies, pharmaceutical therapy; 18 reported individual
factors affecting the quality of life of patients (such as, sleep,
depression, olfactory loss, urinary dysfunction, gait
disturbances, motor complications, dysphagia and
disorientation); 6 related to exhaustive description of some
neurodegenerative diseases; 5 quoted palliative care; 7 stated
the question of the role of caregivers, care networks and care;
4 referred to animal models tests; 2 publications, one reported
a pilot study and another diagnostic models.
The structured research resulted in 11 publications under
the theme that was intended to assess these only 7 articles
were available, and 2 articles were excluded because upon
examination it was found that an article concerned about
psychometric study to measure the quality of life in patients
with tremor and intended to evaluate a range, and in another
article the quality of life was approached after in patients with
Parkinson's surgery. The inclusion and exclusion criteria of the
studies are described in Table 1 and Figure 1.
PRISMA criteria for preferred reporting items for systematic
reviews and meta-analyses (Prisma)ª were applied. The
collected information was compiled and analysed regarding
the year of publication, authors, sample, and country, type of
study/methodology, results and aim.
The cataloguing and identification of repeated references
were made through the computer program EndNote
bibliographic referencing.
Analysis of Results and Discussion
For a better understanding of the systematic literature
review, the analyzed studies were compiled in a summary
table (Table 2). In this table, there were several items: year of
publication/authors, sample, country, methodology,
instruments, results and aims.
Five complete articles which met the inclusion criteria were
analyzed.
A total of 1872 adults from four different countries (United
States, Canada, Croatia and Spain) were also analyzed.
Different dimensions to evaluate the quality of life were
included in the investigation, such as, social, psychological and
environmental, as well as individual’s physical and mental
components.
Similarly, many instruments were used to measure different
dimensions in the study.
A cross-sectional study methodology was clearly
distinguished; the longitudinal methodology was only present
in one study. One article referred a systematic review and
another psychometric study of a scale validation.
The current review revealed few studies about this issue
which is so relevant today, "Quality of life in patients with
neurodegenerative disease."
Neurodegenerative diseases are characterized by a
progressive deterioration of brain function, consequently, with
a significant decrease in patients and their family’s quality of
life [5]. These diseases have a physical, mental and social
impact, and this impact extends far beyond the obvious
characteristic of the disease’ symptoms [3].
The concept quality of life is variously used to indicate
health and functional status, perceived health status,
subjective health, health perception, symptoms, satisfaction,
cognition, functional disability, disorder and well-being [4].
Often in clinical studies these terms are interchangeably used,
although, it is evident that they are different concepts. It is
crucial to emphasize the importance of differentiating health
status and quality of life.
Quality of life presents a wide range of dimensions in
human experience, ranging from those associated with the
basic necessities of life, to the realization of feelings and
satisfaction; even including physical, psychological and social
dimensions [1-3].
In literature, the most studied neurodegenerative diseases
were Parkinson’s, Alzheimer’s disease and Multiple Sclerosis.
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In general, these diseases have typical symptoms, such as,
weakness, fatigue, motor impairment, ataxia, dysphagia,
urinary complications, sensory loss, depression, cognitive
decline, sleep disorders, among others [8-16]. These
symptoms are potential contributors to lower health-related
quality of life.
Table 1 Criteria for inclusion and exclusion in a research “Quality in life of patients with neurodegenerative diseases”
Inclusion Criteria Exclusion Criteria
Use of measuring Quality of Life instruments No use of measuring Quality of Life instruments
Presentation/analysing quantitative/qualitative data No presentation/analyzing quantitative/qualitative data
Psychometric studies of psychometric validation of scale/instruments  
Figure 1 Flowchart - applying the inclusion and exclusion criteria in research
In this literature review, we analyzed the physical
component (PCS) and mental (MCS) of patients with
Parkinson's compared to patients with neurodegenerative
dementia [1]. Several predictors of physical and mental
components were found [1]. Associations with visual
attention/memory functions, visuospatial and executive have
been established and cognitive domains are apparently related
to life’ quality [7].
The impairment of these areas affects negatively the
activities of daily living (ADL) in patients with Parkinson's
disease, not only the basic physical activities, with
instrumental activities of daily living (IADL). Similarly, the
realization of labour is also a compromised activity. It was
found that the value of life in patients with Multiple Sclerosis
influences a lot the quality of life, affecting the labour activity,
labour productivity and increasing the use of health resources.
It should also be noted that the reduction in daily activities are
likely to negatively affect the perception of the same; and can
negatively affect many other areas, such as, self-perception of
cognitive status, emotional well-being, communication skills,
and social stigma.
In general, data suggest that patients with Parkinson's
disease and/or Multiple Sclerosis, present lower levels of
HRQoL in emotional, physical and social terms than the
general population [1,2,5]. The presents studies evaluated the
association of HRQoL in patients with Parkinson's and Multiple
Sclerosis disease, such as, depressive symptoms (high level of
depression) and also (although less prominent and/or less
consistently) deficiencies, high motor difficulties, longer
disease and risk behaviors (smoking, alcohol) [5-7].
For the study and to evaluate these disorders and their
influence on quality of life it is important to use measuring
instruments, its development and validation. The HRQoL
measure, however, it is not easy, because it is not directly
observable and is often assessed by questionnaires about daily
activity, functional capacity, cognitive performance and/or self-
reports (selection of instruments based on evaluations made
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by patients, may have implications for the accuracy of the
information, when faced with clinical information) [4,17].
The most commonly used instruments are the generic
(include individual indicators, health profiles and utilities
measures) are suitable to be used in different populations and
diseases, have advantages of wide applicability in diagnostics,
and consequently have a decision making impact, as well as, in
clinical practice and research. Many have been considered
valid and reliable, increasing their usefulness in clinical scope.
Sometimes, it is used very specific instruments, targeted for a
specific disease. These measurements were repeated in a
number of different neurodegenerative diseases, but are often
criticized due to the lack of specificity and insensitivity to
change over time [2]. Both measures (generic and specific) are
typically used to help assess the effectiveness of the trial and
intervention research, however, there may still be other
approach to the question, when measuring the quality of life
focuses on state aspects of health, self-perception and
perception of others.
Following the importance of instruments to assess quality of
life in patients with neurodegenerative diseases, we found an
article that analyses the psychometric properties of the
WHOQOL-BREF and the new WHOQOL-DIS (for people with
physical disabilities associated with neurodegenerative
diseases). It was also objective of the study, validate these two
instruments and their relationship to quality of life through the
analysis of Hospital Anxiety and Depression Scale - Depression
(HADS-D), Fatigue Assessment Scale (FAS) and Satisfaction
With Life (SWL), Multiple Sclerosis Impact Scale (MSIS-29),
Parkinson's Disease Questionnaire (PDQ-39) [5,7].
WHOQOL-BREF is a generic QL questionnaire, with items
grouped into four domains (physical, psychological, social and
environmental) and two global items related to overall QL and
satisfaction with health, which reflects social relations and the
environment, these areas are often overlooked in other
questionnaires. WHOQOL-DIS assesses the overall disability
impact, focuses mainly on psychosocial aspects relevant to
adults with disabilities and captures the impact of disability in
people's lives [5]. Thus, these instruments can provide useful
information along the continuum of care for people with
neurodegenerative disease, from early diagnosis to more
severe states, ambulatory and hospital services, health and the
level of social assistance. Therefore, these instruments appear
to be promising tools to monitor QL changes [4].
Summary of methodological limitations
The methodology selected for inclusion and exclusion of
these studies, always limits the results obtained, leaving out
many valid data studies, especially in this emerging area such
as “quality of life in patients with neurodegenerative diseases”,
so that they can be excluded relevant factors to the
understanding of the subject.
The lack of publications in this area, also conditioned this
selection, analysis and generalization of the results. They
approached to some assessment of the measure of quality of
life instruments, however, not consistent with a single
instrument, conditioned evaluation and a more overview
comprehensive of different studies. The use of a single
measuring instrument, would have allowed an easier and a
more correct comparison of the identified variables and the
nature of the instrument would have allowed to cover a
greater number of factors.
We found limitations in the analyzed articles: not
representative sample of the population [1], the relevance of
self-report (which can condition the individual and clinical
characteristics) [1,4,6], the cross-sectional design of the study
[1,6], the use of non-specific resources for pathologies [6], the
data generalization to clinical observations [7].
Implications for Practice
Neurodegenerative diseases are, undoubtedly, a growing
problem in health sciences, due to increased life expectancy
and unhealthy life. Although the mechanisms of these diseases
are still far from being clarified, several studies have been
made in this direction, to promote and learn to deal with these
conditions.
The literature review aimed to present the information
obtained about "Quality of life in patients with
neurodegenerative disease". Despite the scarce publications
found, this study aimed to discover what has been done and
emphasize the importance to develop future research.
The current review suggest, new studies about measuring
instruments to quality life in patients with neurodegenerative
diseases, build (more specific items, for each pathology),
validate and apply.
More longitudinal studies are important, for example, a
gender differences study. Furthermore, it is important to
extend these studies to other countries, including the
Portuguese-Brazilian community.
Another underlying implication of this study is related to a
great ambiguity of terms, and in future studies should be
interesting to standardize anthologies descriptors factors
associated with quality of life/neurodegenerative diseases.
Conclusion
Neurodegenerative diseases are a growing worldwide
problem, due to the aging population and to the risk behaviour
that it shows. Improving the quality of life of individuals is as
important as investing in prevention and cure of diseases.
This study sought to address the issue and to find that there
is still much to do. Also, it intends to draw attention to the
importance of recognizing and documenting the subjective
impact of the disease. Individual, biological and environmental
factors were mentioned to be directly related to the quality of
life in patients with neurodegenerative diseases. The
knowledge of these factors can be useful in reducing
emotional, psychological and social charge, promoting the
well-being and in improving the quality of life of these
patients.
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Thus, more research is needed, more interventions, and
more tools are needed for assessing the impact of quality of
life in degenerative pathologies, improving the quality of life of
these patients.
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Table 2 Summary of information from five relevant articles met our inclusion criteria in the study of “Quality of life in patients
with neurodegenerative diseases”
Author/
Year
Sample Countr
y
Methodology Instruments Dimension
s
evaluated
Results Aim
Chekani
et al.,
2015 [1]
N=796 adults with
Neurodegenerative
Diseases
(International
Classification of
Diseases
(ICD9CM)) –
Database
2002-2011 Medical
Expenditure Panel
Survey (MEPS)
United
States
Longitudinal,
Retrospective
cross-sectional
design to
examine HRQoL
among patients
with PD and
neurodegenerati
ve dementia
HRQoL
(include
physical,
psychological
and social
dimension)
(Wilson and
Cleary Model)
PCS,
MCS,
ADL
IADL
Average age 74 years; Most
patients with PD were male,
and most neurodegenerative
dementia patients were female.
Patients with PD showed a
lower PCS analysis and were
less likely to seek help for IADL
MCS were not found different
results among patients.
ADL, there were no significant
differences between patients
with PD and neurodegenerative
dementia.
Individual, biological and
environmental factors have
been associated with quality of
life in patients with PD and
neurodegenerative dementia.
(1) assess quality of
health of life in
Parkinson's disease
and
neurodegenerative
dementia, (2) identify
predictors of PCS
and MCS in patients
with
neurodegenerative
diseases, and (3) to
identify predictors of
ADL and IADL in
patients with
neurodegenerative
diseases.
Gupta
et al.,
2014 [6]
N= 536 with MS
(N=74 control)
United
States
Cross
study analysed
cross-sectional
data from the
2009 US
National Health
and Wellness
Survey (NHWS),
HRQoL
(include
physical,
psychological
and social
dimension)
(Wilson and
Cleary Model)
PCS
MCS
The significant differences
between MS and controls - MS
can interfere too much with
QOL, work productivity and
increase the use of health
resources.
Increased severity of MS may
be accompanied by a greater
involvement of labour activity,
lower productivity at work and
increased use of health care.
Transition between degrees of
severity of the disease may not
be linear and increasing the
severity of MS is associated
with worse health outcomes.
Compare the quality
of life of health,
labour productivity,
commitment, activity
and resource
utilization among
patients with MS and
controls, as well as
through MS patients
with different self-
reported with severity
disease.
Lucas-
Carrasc
o et al.,
2011 [5]
N= 149 (84 with
MS and 65 with PD
Spain Psychometric
properties
WHOQOL-BREF
and WHOQOL-
DIS
WHOQOL-
BREF;
WHOQOL-
DIS;
PDQ-39;
MSIS-29;
FAS;
HADS-D;
SWL Scale
psychosoci
al, social
and
environmen
tal
dimension
WHOQOL-BREF and
WHOQOL-DIS - acceptable
levels of acceptability, internal
consistency, and validity (high
correlations of the WHOQOL-
BREF and WHOQOL-DIS with
HADSD scales, DO, SWL,
MSIS-29 and PDQ-39). There
is the self-perception and self-
reporting, with significant
differences in three domains
(physical, psychological and
environmental). Relative
deficiency in life, participants
with mild to moderate disease
had improved quality of life in
all areas compared to serious
illness.
WHOQOL-BREF - two domains
of quality of life (social relations
and environment) are often
omitted in other measures.
WHOQOL- DIS - psychosocial
aspects relevant to adults with
disabilities and captures the
impact of disability on a
person's life.
Using the WHOQOL-
BREF and
WHOQOL-DIS to
measure quality of
life in people with
physical disabilities
caused by
neurodegenerative
disorders.
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Klepac
et al.,
2008 [7]
N= 124 with PD Croatia Cross clinical PDQ-39 to
evaluate
HRQoL and
Beck's
Depression
Inventory
(BDI) to
quantify
depression
Cognitive
performanc
e
Preliminary Assessment
(univariate analysis) indicated
visual attention / memory,
visuospatial and executive
functions such as cognitive
domains apparently related to
HRQL.
The results strongly suggest a
better visual attention / memory
and better visuospatial and
executive functioning, are
independently associated with
better HRQOL.
Explore the
relationship between
cognitive
performance and
HRQOL in non-
demented patients
with Parkinson's
disease.
Kern e
Brown,
2004 [4]
N= 193
(quantitative
studies Quality of
Life and Health
Status)
Canada Systematic
review
 Quality of
Life,
Health
Physics;
Mental
health;
Health
Lower mental health and quality
of life in patients with chronic
progressive neurodegenerative
disease (CPND).
Differential receptivity of mental
health appears to be higher in
multiple sclerosis.
Apparent lack of difference in
physical mental-health health
responses in ALS, the
responsiveness of
parkinsonism may reflect the
small number of paired
comparisons or the negative
influence of cognitive
dysfunction in the development
or change of response
assessment.
Response change is also an
active response in the cognitive
process that is limited in
degenerative neurological
conditions associated with
dementia.
Review the case,
adaptation disease
could be measured in
progressive chronic
neurological
diseases (CPND) by
means of longitudinal
comparisons paired
with quality of life
(QoL) and health
status (HS) and
mental health (MH)
and physical health
(PH) domains of
quality of life
instruments.
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